Liquidia Technologies appoints new VP, Business Development & Strategy

Particle engineering specialist Liquidia Technologies announced that it has hired Jason Adair as VP, Business Development & Strategy. Adair was most recently Executive Director of Corporate Development at BioCryst and was previously Director of Business Development at MedImmune.

Liquidia CEO Neal Fowler commented, “Jason brings extensive business development and commercial strategy experience to Liquidia, as well as a track record of solid leadership. We continue to demonstrate the power and flexibility of our PRINT technology platform in overcoming product development challenges across a wide range of therapeutic areas. We believe that Jason’s diverse experience in securing domestic and international partnerships will be key in the expanded use of PRINT across our industry and to the continued growth of our Company. We are very pleased to have him as part of our leadership here at Liquidia.”

In September 2015, Liquidia announced that GSK had exercised an option for exclusive rights to develop inhaled drugs based on Liquidia’s PRINT particle technology.

Read the Liquidia press release.

Share

published on

December 9-December 11: DDL 2026, Edinburgh, Scotland

April 27-30: RDD Europe 2027, Antibes, France

June 30: RespireX 2027, Boston, MA, USA